Shasun Pharmaceuticals gains on completing USFDA inspection at UK facility

14 Nov 2014 Evaluate

Shasun Pharmaceuticals is currently trading at Rs. 212.95, up by 2.00 points or 0.95% from its previous closing of Rs. 210.95 on the BSE.

The scrip opened at Rs. 214.00 and has touched a high and low of Rs. 217.55 and Rs. 210.40 respectively. So far 60,157 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 2 has touched a 52 week high of Rs. 234.35 on 26-Aug-2014 and a 52 week low of Rs. 67.70 on 25-Mar-2014.

Last one week high and low of the scrip stood at Rs. 217.55 and Rs. 197.65 respectively. The current market cap of the company is Rs. 1,280.00 crore.

The promoters holding in the company stood at 39.49% while Institutions and Non-Institutions held 17.81% and 42.70% respectively. Shasun Pharmaceuticals, a global pharmaceutical organization offering world class capabilities and facilities, has successfully completed United States Food and Drug Administration (USFDA) inspection at its manufacturing facility at Dudley England. The USFDA audit was held on first week of November 2014.

On completion of the inspection, the USFDA inspector concluded that the facility, systems and practices comply with USFDA requirements with no observations reported on the form 483.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.